Finally, a successful adjuvant therapy for high-risk melanoma

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 1-3

  Balch, Charles M ^a   Buzaid, Antonio C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EDITORIAL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030067823     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.1     Document Type: Editorial

References (0)